{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:59:35Z","timestamp":1791928775403,"version":"4.3.4"},"reference-count":64,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"14","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2021,11,10]]},"DOI":"10.1167\/iovs.62.14.8","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T19:27:19Z","timestamp":1636572439000},"page":"8","source":"Crossref","is-referenced-by-count":23,"title":["Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model"],"prefix":"10.1167","volume":"62","author":[{"given":"Jessica V.","family":"Kaczmarek","sequence":"first","affiliation":[{"name":"Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carley M.","family":"Bogan","sequence":"additional","affiliation":[{"name":"Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janene M.","family":"Pierce","sequence":"additional","affiliation":[{"name":"Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai K.","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheau-Chiann","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli L.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Wade","family":"Calcutt","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Bridges","sequence":"additional","affiliation":[{"name":"Warren Center for Neuroscience Drug Discovery at Vanderbilt, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Warren Center for Neuroscience Drug Discovery at Vanderbilt, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Richmond","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Tennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee, United States"},{"name":"Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States"},{"name":"Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"Daniels","sequence":"additional","affiliation":[{"name":"Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States"},{"name":"Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, United States"},{"name":"Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"8","key":"bib1","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.ophtha.2007.12.014","article-title":"A phase I\/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results","volume":"115","author":"Abramson","year":"2008","journal-title":"Ophthalmology"},{"issue":"8","key":"bib2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/bjophthalmol-2011-301016","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"bib3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.sjopt.2013.06.003","article-title":"Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives","volume":"27","author":"Munier","year":"2013","journal-title":"Saudi J Ophthalmol"},{"issue":"12","key":"bib4","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","article-title":"The International Classification of Retinoblastoma predicts chemoreduction success","volume":"113","author":"Shields","year":"2006","journal-title":"Ophthalmology"},{"issue":"5","key":"bib5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0002-9394(02)01348-X","article-title":"Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation","volume":"133","author":"Shields","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"bib6","doi-asserted-by":"publisher","first-page":"e0146582","DOI":"10.1371\/journal.pone.0146582","article-title":"Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma","volume":"11","author":"Abramson","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"bib7","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/cancers13092216","article-title":"Effect of intravenous chemotherapy regimen on globe salvage success rates for retinoblastoma based on disease Class-A meta-analysis","volume":"13","author":"Daniels","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"bib8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/IIO.0000000000000155","article-title":"Evolution of chemotherapy approaches for the treatment of intraocular retinoblastoma: a comprehensive review","volume":"57","author":"Yuan","year":"2017","journal-title":"Int Ophthalmol Clin"},{"issue":"10","key":"bib9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.ophtha.2017.04.010","article-title":"Retinoblastoma vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery chemosurgery with or without intravitreous and periocular chemotherapy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"12","key":"bib10","doi-asserted-by":"publisher","first-page":"e26696","DOI":"10.1002\/pbc.26696","article-title":"Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era","volume":"64","author":"Berry","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"bib11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ophtha.2015.01.017","article-title":"The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan","volume":"122","author":"Francis","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"bib12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ophtha.2017.05.034","article-title":"Not all seeds are created equal: seed classification is predictive of outcomes in retinoblastoma","volume":"124","author":"Berry","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"bib14","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1167\/iovs.18-25346","article-title":"Rabbit model of intra-arterial chemotherapy toxicity demonstrates retinopathy and vasculopathy related to drug and dose, not procedure or approach","volume":"60","author":"Daniels","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"bib15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamaophthalmol.2013.2065","article-title":"Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings","volume":"131","author":"Tse","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"bib16","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ophtha.2014.03.028","article-title":"Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study","volume":"121","author":"Francis","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"bib17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"bib18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10792-013-9851-2","article-title":"Pathological findings in enucleated eyes after intravitreal melphalan injection","volume":"34","author":"Ghassemi","year":"2014","journal-title":"Int Ophthalmol"},{"issue":"1","key":"bib19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/IIO.0000000000000154","article-title":"Alternative chemotherapeutic agents for the treatment of retinoblastoma using the intra-arterial and intravitreal routes: a path forward toward drug discovery","volume":"57","author":"Yuan","year":"2017","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"bib20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3928\/23258160-20170130-09","article-title":"Preclinical acute ocular safety study of combined intravitreal carboplatin and etoposide phosphate for retinoblastoma","volume":"48","author":"Mohney","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"bib21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/bjophthalmol-2011-300829","article-title":"Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds","volume":"96","author":"Smith","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"bib22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/bjophthalmol-2020-316588","article-title":"Is intravitreal topotecan toxic to retinal function?","volume":"105","author":"Nadelmann","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"bib23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/bjophthalmol-2017-310641","article-title":"Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma","volume":"102","author":"Rao","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"bib24","article-title":"Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study [published online ahead of print May 10, 2021]","author":"Bogan","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"bib25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1167\/iovs.17-22302","article-title":"Pharmacokinetics, tissue localization, toxicity, and treatment efficacy in the first small animal (rabbit) model of intra-arterial chemotherapy for retinoblastoma","volume":"59","author":"Daniels","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"bib26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1534-5807(02)00360-X","article-title":"The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation","volume":"3","author":"Fajas","year":"2002","journal-title":"Dev Cell"},{"issue":"1","key":"bib27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bbrc.2004.02.044","article-title":"Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitro","volume":"316","author":"Takaki","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"bib28","first-page":"5049","article-title":"The COOH-terminal region of pRb2\/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter","volume":"58","author":"Stiegler","year":"1998","journal-title":"Cancer Res"},{"issue":"18","key":"bib29","doi-asserted-by":"publisher","first-page":"10493","DOI":"10.1073\/pnas.95.18.10493","article-title":"The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase","volume":"95","author":"Ferreira","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"31","key":"bib30","doi-asserted-by":"publisher","first-page":"28507","DOI":"10.1074\/jbc.M413687200","article-title":"Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein","volume":"280","author":"Gray","year":"2005","journal-title":"J Biol Chem"},{"issue":"21","key":"bib31","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.1128\/MCB.23.21.7719-7731.2003","article-title":"Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition","volume":"23","author":"Siddiqui","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"8","key":"bib32","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/jcp.24329","article-title":"RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis","volume":"228","author":"Di Fiore","year":"2013","journal-title":"J Cell Physiol"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"101358","DOI":"10.1016\/j.mex.2021.101358","article-title":"Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: assessment of pharmacokinetics, toxicity and efficacy using a rabbit model","volume":"8","author":"Daniels","year":"2021","journal-title":"MethodsX"},{"issue":"2","key":"bib34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.30802\/AALAS-CM-18-000146","article-title":"Severe periocular edema after intraarterial carboplatin chemotherapy for retinoblastoma in a rabbit (Oryctolagus cuniculus) model","volume":"70","author":"Oatess","year":"2020","journal-title":"Comp Med"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"108439","DOI":"10.1016\/j.exer.2021.108439","article-title":"Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: efficacy, toxicity and stability in rabbits models and patients","volume":"204","author":"Bogan","year":"2021","journal-title":"Exp Eye Res"},{"issue":"3","key":"bib36","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1364\/BOE.9.001244","article-title":"Quantitative biometry of zebrafish retinal vasculature using optical coherence tomographic angiography","volume":"9","author":"Bozic","year":"2018","journal-title":"Biomed Opt Express"},{"issue":"2","key":"bib37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10633-004-3924-5","article-title":"Standardized full-field electroretinography in rabbits","volume":"109","author":"Gjorloff","year":"2004","journal-title":"Doc Ophthalmol"},{"issue":"22","key":"bib38","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1111\/febs.2016.283.issue-22","article-title":"How do tumor cells respond to HDAC inhibition?","volume":"283","author":"Newbold","year":"2016","journal-title":"FEBS J"},{"issue":"10","key":"bib39","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/ijms20102415","article-title":"p53 at the crossroads between different types of HDAC inhibitor-mediated cancer cell death","volume":"20","author":"Mrakovcic","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"bib40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/0008-5472.CAN-07-2531","article-title":"Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells","volume":"68","author":"Heller","year":"2008","journal-title":"Cancer Res"},{"issue":"13","key":"bib41","first-page":"3735","article-title":"Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays","volume":"63","author":"Sato","year":"2003","journal-title":"Cancer Res"},{"issue":"18","key":"bib42","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/sj.onc.1210041","article-title":"Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer","volume":"26","author":"Zhong","year":"2007","journal-title":"Oncogene"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"394730","DOI":"10.1155\/2011\/394730","article-title":"Rabbit model of retinoblastoma","volume":"2011","author":"Kang","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"bib44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10633-008-9164-3","article-title":"Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma","volume":"119","author":"Brodie","year":"2009","journal-title":"Doc Ophthalmol"},{"issue":"6","key":"bib45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000486098","article-title":"Integrated treatment during the intravitreal melphalan era: concurrent intravitreal melphalan and systemic chemoreduction","volume":"4","author":"Berry","year":"2018","journal-title":"Ocul Oncol Pathol"},{"issue":"2","key":"bib46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv Cancer Res"},{"issue":"12","key":"bib48","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"bib49","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/ijms20071616","article-title":"Mechanism of action for HDAC inhibitors-insights from omics approaches","volume":"20","author":"Li","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"20","key":"bib50","doi-asserted-by":"publisher","first-page":"10612","DOI":"10.1093\/nar\/gkz816","article-title":"Histone deacetylase 3 controls a transcriptional network required for B cell maturation","volume":"47","author":"Stengel","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"bib51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000001275","article-title":"Ocular pharmacology of chemotherapy for retinoblastoma","volume":"37","author":"Schaiquevich","year":"2017","journal-title":"Retina"},{"issue":"4","key":"bib52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1089\/jop.2015.0088","article-title":"Pharmacokinetics of melphalan after intravitreal injection in a rabbit model","volume":"32","author":"Buitrago","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"bib53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.exer.2010.03.009","article-title":"Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment","volume":"91","author":"Buitrago","year":"2010","journal-title":"Exp Eye Res"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"2","key":"bib55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/sj.onc.1209025","article-title":"E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer","volume":"25","author":"Lu","year":"2006","journal-title":"Oncogene"},{"issue":"8","key":"bib56","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrm3841","article-title":"The growing landscape of lysine acetylation links metabolism and cell signalling","volume":"15","author":"Choudhary","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"bib57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteins modulates cellular signalling at multiple levels","volume":"41","author":"Spange","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"bib58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1189\/jlb.1013565","article-title":"Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1","volume":"95","author":"Jeong","year":"2014","journal-title":"J Leukoc Biol"},{"issue":"7","key":"bib59","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bcp.2004.12.017","article-title":"Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf","volume":"69","author":"Wagner","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"15","key":"bib60","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1074\/jbc.M512719200","article-title":"Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity","volume":"281","author":"Tan","year":"2006","journal-title":"J Biol Chem"},{"issue":"2","key":"bib61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mol2.v14.2","article-title":"UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis","volume":"14","author":"Kim","year":"2020","journal-title":"Mol Oncol"},{"issue":"5","key":"bib62","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.2012.156.issue-5","article-title":"The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells","volume":"156","author":"Baumann","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"bib63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.bbrc.2011.03.068","article-title":"Overexpression of HDAC1 induces cellular senescence by Sp1\/PP2A\/pRb pathway","volume":"407","author":"Chuang","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"bib64","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1074\/jbc.M110.198473","article-title":"Cyclin-dependent kinase-mediated phosphorylation of RBP1 and pRb promotes their dissociation to mediate release of the SAP30.mSin3.HDAC transcriptional repressor complex","volume":"286","author":"Suryadinata","year":"2011","journal-title":"J Biol Chem"},{"key":"bib13","first-page":"1184","article-title":"Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture","volume-title":"Retina","author":"Shields","year":"2016"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2778064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:29Z","timestamp":1791927089000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2778064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":64,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.62.14.8","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,10]]}}}